Tag:
pharmaceutical sales and marketing
Latest Headlines
Latest Headlines
High court to weigh data-mining laws
The U.S. Supreme Court has decided to consider a case that could change the face of drug marketing. At issue is whether market research firms can collect prescription information and resell it to
Novartis, Sanofi debut first Android apps
Now that new Android gadgets hit the market about once a week, Big Pharma has decided to add its voice to that platform. Sanofi-Aventis ( $SNY ) and Novartis ( $NVS ) have both introduced new Android
GSK pitches Votrient rebate if trial favors Sutent
Drugmakers have held out plenty of different carrots to induce the U.K.'s cost-effectiveness watchdog to accept expensive meds for use on the National Health Service. Companies have offered paybacks
FDA won't deliver on social media rules
Once again, the FDA fails to meet a deadline. This time, it's the promised guidelines on using the Internet and social media for marketing--the guidelines that drugmakers have been anxiously
Pfizer lets reps race with e-sampling system
In the ongoing tussle between human and machine--in this case, pharma reps and online marketing--Pfizer ( $PFE ) has awarded new points to the machine. But as the Wall Street Journal Health Blog
Drug, device reps add iPads to tool belt
If Santa doesn't bring you an iPad this holiday season, then maybe your pharma employer will. Drug and device firms are arming their sales people with the tablet devices by the thousands, the Wall
Primary-care docs think GSK reps are tops
In the latest sales popularity contest, GlaxoSmithKline ( $GSK ) reps are the prom kings and queens of pharma marketing. According to the market research firm SDI's 2010 study, primary care doctors
Primary care docs want samples from reps
What do doctors really prefer: A live sales rep or a computer? According to a new survey, the human being wins--at least for primary care doctors collecting drug samples. Some 73 percent of
Big change in market-access strategies, execs say
What's the biggest change for today's pharma executive? Market access strategies, according to a survey by Cegedim Dendrite. Forty percent cited it as the part of their business undergoing the
AZ replaces Nexium sales reps with call center
What if a call center worked just as well as hundreds of sales reps on the street? That's the question raised by BNet Pharma after AstraZeneca ( NYSE: AZN ) disbanded almost all of its in-person sales
